SBIR-funded as Aurora Bio Inc, now doing business as Attralus, the firm is developing novel pan-amyloid removal (PAR) therapeutics designed directly to bind to and remove toxic amyloid - an approach that portends to open the potential ofreat and reverse disease in all types of systemic amyloidosis. With some 80% of patients with systemic amyloidosis being undiagnosed, the condition includes a diverse group of debilitating, progressive, and often fatal diseases - characterized by the accumulation of amyloid in vital organs.. There are no therapies that remove amyloid and reverse disease: no therapies capable of treating all types and stages of systemic amyloidosis. Attralus is developing novel pan-amyloid removal (PAR) therapeutics designed to eliminate toxic, disease-causing amyloid in organs and tissues of patients with systemic amyloidosis. The firm's proprietary technology has enabled development of novel biologics - as well as an amyloidosis-specific imaging agent that now propels the effort to identify and treat all stages and types of patients with this life-threatening disease.
